Delivering Model T CARs

A Fred Hutchinson Cancer Research Center team believes its two chimeric antigen receptor (CAR) delivery platforms could lower immunological and financial costs enough to turn engineered immune cell therapies into widely accessible treatments. With two studies on their implant- and nanoparticle-based CAR technologies published in the last two weeks, the researchers are seeking industry partners to turn both platforms into therapeutics.

Matthias Stephan, the principal investigator behind the studies, told BioCentury his goal was to broaden the use of CAR and other cellular immunotherapies by developing versions of the technologies that don't require wiping out the patient's immune system or growing tens of millions of cells in culture...